TruSight Oncology Platform Reagents

A set of NGS platform reagents for detecting cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included. Read More...
Select Product(s)

TruSight® Oncology Library Prep



TruSight Oncology DNA Library Prep



TruSight® Oncology RNA Library Prep



TruSight® Oncology Enrichment



Product Highlights

These enrichment-based next-generation sequencing (NGS) reagents enable simultaneous analysis of DNA and RNA, and can cover a wide range of cancer variant types. This methodology provides laboratories with a deep view into the genetics of cancer.

  • Accurate Results from Low-Quality Samples1
    Enables variant detection with as little as 40 ng DNA and RNA input, maximizing the results from precious formalin-fixed, paraffin-embedded (FFPE) samples.
  • Supports Comprehensive Coverage of Cancer-Related Variants
    Allows the assessment of multiple variant types in one assay using DNA and RNA which creates efficiencies in sample usage, time, and cost.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.
  • Flexible Applications
    Enrichment-based workflow allows for a wide variety of content, input types, and applications.

See the Entire TruSight Oncology Product Family

Frequently Purchased Together


Method-Specific Workflow Example


Related Products

TruSight Oncology 500

Assay targeting multiple variant types, including microsatellite instability (MSI) and tumor mutational burden (TMB).

TruSight Oncology 500 ctDNA v2

Enable CGP with a pan-cancer panel capable of detecting key IO gene signatures (TMB, MSI) plus all main variant classes from ctDNA in blood plasma.

TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.

  1. Data on file. Illumina, Inc. March 2017.